Content Status
Type
Linked Node
Evidence for efficacy of different drugs under TPT
Learning ObjectivesDiscuss the evidence available for efficacy of different drugs and regimens for TB prevention across the globe
Resources for 6 H:
1. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;(1) Available at: https://pubmed. ncbi.nlm.nih.gov/20091503/. Accessed March 2020.
2. Zenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ. Treatment of Latent Tuberculosis Infection. Ann Intern Med. 2017 Aug 1;167(4):248–55.
For 3RH:
Stagg HR, Zenner D, Harris RJ, Muñoz L, Lipman MC, Abubakar I. Treatment of Latent Tuberculosis Infection. Ann Intern Med. 2014 Sep 16;161(6):419–28.
Spyridis NP, Spyridis PG, Gelesme A, Sypsa V, Valianatou M, Metsou F, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis. 2007 Sep 15;45(6):715–22
For 1HP:
1. Swindells S, Ramchandani R, Gupta A et. al. BRIEF TB/A5279 Study Team. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med. 2019 Mar 14;380(11):1001-1011. doi: 10.1056/NEJMoa1806808. PMID: 30865794; PMCID: PMC6563914.
2 World Health Organization. WHO operational handbook on TB: Module 1 – TB Preventive Treatment, 2020
Content Creator
Reviewer
- Log in to post comments